Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris
Status:
Not yet recruiting
Trial end date:
2022-12-26
Target enrollment:
Participant gender:
Summary
This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel
controlled design. The subjects in the study group were given double-blind drugs, and they
were taken (orally) after dinner every day according to the requirements of clinical trial
scheme.